Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

nanoparticles

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

- PMLiVE

WHO announces new mRNA vaccine development initiative against human avian influenza

H5N1 was responsible for 889 cases and 463 deaths across 23 countries from 2003 to 2024

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

- PMLiVE

MIT protein study could help accelerate development of new antibiotics

Histidine kinase is a crucial bacterial protein that regulates processes, including antibiotic resistance

- PMLiVE

Researchers develop microneedle patch to reverse hair loss caused by alopecia areata

The autoimmune skin condition currently affects more than six million people in the US

- PMLiVE

UKHSA and The Pirbright Institute collaborate to develop vaccines against henipaviruses

There are currently no licensed vaccines or treatments for the Nipah virus

- PMLiVE

AstraZeneca announces plans to invest £650m in UK to boost life sciences sector

The investment will also help to enhance public health protection and pandemic preparedness in the UK

- PMLiVE

New nanoparticle to deliver vaccines and generate strong immune responses at lower dose

MOF activates the innate immune system through TLRs to provoke strong immune responses

- PMLiVE

New drug interaction model could improve drug safety and effectiveness

The model found that the antibiotic doxycycline could interact with a common blood thinner, warfarin

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links